Last reviewed 2026-04-20 · How we verify

Hexalen (ALTRETAMINE)

Hexalen (Altretamine) is a small molecule alkylating drug developed by Eisai Inc, targeting Cytochrome P450 1A2. It was FDA-approved in 1990 for the treatment of malignant ovarian tumors. As an off-patent medication, Hexalen is no longer protected by active patents, allowing for potential generic competition. Despite its off-patent status, Eisai Inc remains the current owner of the medication. Key safety considerations include the need for careful monitoring of patients due to potential side effects.

At a glance

Approved indications

• Malignant tumor of ovary

Common side effects

No common side effects on file.

Key clinical trials

• Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
• Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments (PHASE2)
• Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy (PHASE2)
• A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
• Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects (PHASE1)
• Thrombo-inflammation in Acute Neurovascular Diseases: Definition of New Therapeutic Targets (TARGETS)
• E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in Adults (PHASE1)
• Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.